Page 2 - Onward Therapeutics News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Onward therapeutics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Onward Therapeutics Today - Breaking & Trending Today

Biomunex appoints Dr. Simon Plyte, PhD, as Chief Scientific Officer to boost clinical and business d

Dr. Simon Plyte will help Biomunex accelerate preclinical and early clinical development of bi- and multi-specific antibodies in the treatment of cancer and ensure evolution of the BiXAb® platformDr. Plyte will also join the scientific advisory. ....

United States , France General , United Kingdom , Simon Plyte , Pierre Emmanuel Gerard , Institut Curie , Boehringer Ingelheim Biberach , Ontario Cancer Institute Toronto , Olivier Lantz Institut Curie Clinical Immunology Laboratory , Boehringer Ingelheim , University Of Kiel , University Of Portsmouth , Ludwig Institute For Cancer Research London , Matthias Peipp Head Of Division Antibody , Biomunex Pharmaceuticals , Nerviano Medical Sciences , Chief Scientific Officer , New Chemical Entities , New Biological Entities , Onward Therapeutics , Sebastian Amigorena , Olivier Lantz , Clinical Immunology Laboratory , Matthias Peipp , Senior Director , Molecular Partners ,

PharmaEngine's Yeh first female laureate at ITRI

PharmaEngine Inc (智擎生技) founder Grace Yeh (葉常菁) has become the Industrial Technology Research Institute’s (ITRI, 工業技術研究院) first female fellow since it started awarding business leaders with fellowships 10 years ago.
ITRI chairman Lee Chih-kung (李世光) told the 10th ITRI Laureates award ceremony on Tuesday that Yeh’s induction was significant, because in addition to being the institute’s 50th laureate, she is its first female fellow.
Yeh said she was surprised to learn that she was the first woman to be awarded.
Taiwan has many outstanding female leaders in the field of technology, but they have so far been ignored by the laureate selection committee, ....

T Ai Pei , Industrial Technology Research Institute , Kao Hsiung , Lin Rong Jin , Lee Chih Kung , Pharmaengine Yeh , Taiwan Bio Industry Organization , University Of South Carolina , Pharmaengine Inc , Drug Administration , Center Laboratories Inc , Gengine Inc , Grace Yeh , Onward Therapeutics , Medical University , The Taipei Times ,

Biomunex immunotherapy project awarded grant of close to €3m

Biomunex Pharmaceuticals, a French company focused on the discovery and development of bi- and multi-specific antibodies, sees its BiXAb5 project receive nearly €3m (US$3.5m) in the form of a grant from the French government. ....

Pierre Emmanuel Gerard , Institut Curie , Paris Based Institut Curie , Onward Therapeutics , Markets Amp Regulations , Cell Amp Gene Therapies , Solid Tumor , T Cell ,

Onward Therapeutics takes first steps of its buy and build strategy Startupticker.ch

Headed by the successful biotech entrepreneur Grace Yeh, Onward Therapeutics pursues a buy and build strategy with the goal to identify and develop innovative medicines for the treatment of cancer. The company which was founded in 2020 and is based at Biopôle has now closed the first contracts with two biotech start-ups.
Onward Therapeutics acquires licenses for potential development candidates and investing in their partners with platform technologies. The company is led by an experienced team.Grace Yeh, President and CEO of Onward Therapeutics was Founder, President and Chief Executive Officer of PharmaEngine, Inc., a publicly traded commercial stage oncology company headquartered in Taipei, Taiwan with a wholly owned subsidiary in Paris, France. Its market capitalization on the Taipei Exchange exceeded US$1 billion. ....

T Ai Pei , France General , Alain Herrera , Pharmaengine Inc , Taipei Exchange , Biomunex Pharmaceuticals , Onward Therapeutics , Grace Yeh , Chief Executive Officer , Wednesday Onward , Chief Medical Officer , டி ஐ பேய் , பிரான்ஸ் ஜநரல் , அலன் ஹெர்ரெரா , தைப்பே பரிமாற்றம் , தொடர்ந்து சிகிச்சை , கருணை ஆமாம் , தலைமை நிர்வாகி அதிகாரி , புதன்கிழமை தொடர்ந்து , தலைமை மருத்துவ அதிகாரி ,

EMERCell Signs Strategic Partnership with Onward Therapeutics for the Development of its NK Cell Therapy Technology

(1)
EMERCell, a biotechnology company developing immunotherapies and cell-based therapies for oncology targets through to pharmaceutical development, announces the signature of a strategic partnership with Onward Therapeutics. The significant investment, of a confidential amount, will be made in three instalments that will allow EMERCell to reach the first human clinical trials.
We are delighted to partner with Onward Therapeutics, whose teams have recognized expertise in the development of new drugs in oncology and with whom we have strong synergies. Their participation is a recognition of our expertise and will allow us to accelerate our development, said Patrick Henno, founder and Chairman of EMERCell. ....

Patrick Henno , Kostenloser Wertpapierhandel , Caroline Carmagnol , University Hospital Of Montpellier , Institute Of Regenerative Medicine , Saint Eloi University Hospital Center , University Of Montpellier , Onward Therapeutics , University Hospital , Regenerative Medicine , Natural Killer , Occitanie Region , பல்கலைக்கழகம் மருத்துவமனை ஆஃப் மான்ட்பெல்லியர் , நிறுவனம் ஆஃப் மீளுருவாக்கம் மருந்து , பல்கலைக்கழகம் ஆஃப் மான்ட்பெல்லியர் , தொடர்ந்து சிகிச்சை , பல்கலைக்கழகம் மருத்துவமனை , மீளுருவாக்கம் மருந்து , இயற்கை கில்லர் , ஒக்ஸிததனிே பகுதி ,